Luciferase Reporter Cell Line - TM3

The TM3 cell line is a well-established, non-tumorigenic murine model originally derived from the Leydig cells of a normal prepubertal BALB/c mouse testis. Cultured as an adherent monolayer, these somatic cells are functionally characterized by their responsiveness to luteinizing hormone (LH) and their capacity for steroidogenesis, serving as a standard physiological surrogate for primary Leydig cells. The Luciferase Reporter Cell Line - TM3 elevates this foundational reproductive model through stable lentiviral transduction, engineering the cells to constitutively express the firefly luciferase enzyme. This genetic integration guarantees that the cells continuously produce a quantifiable bioluminescent signal when exposed to the substrate D-luciferin. Crucially, this modification transforms the parental line into a highly sensitive tracking tool while strictly preserving its fundamental endocrine phenotype, hormone responsiveness, and baseline physiological behavior.

Leveraging its accurate representation of testicular somatic cell function, this reporter line is heavily utilized in preclinical reproductive biology and endocrine toxicology. In vitro, the robust constitutive bioluminescence streamlines high-throughput cell viability and cytotoxicity assays. Researchers depend on this quantifiable optical readout to rapidly assess the reproductive toxicity of environmental endocrine-disrupting chemicals (EDCs), heavy metals, and novel pharmacological compounds targeting male steroidogenic pathways. In vivo, the continuous luminescent signal enables the non-invasive tracking of engineered TM3 cells following experimental transplantation. By employing bioluminescence imaging (BLI), scientists can dynamically monitor cell survival, engraftment, and localization within the testicular microenvironment in living animals over time. This longitudinal approach minimizes the need for repeated endpoint sacrifices, yielding precise spatial and temporal data that accelerates discoveries in male infertility treatments, reproductive pharmacology, and gonadal tissue engineering.